Current Problems and the Future of Antiretroviral Drug Trials

Abstract

Now that a growing arsenal of new and potential anti-HIV drugs exists, debate and discussion about the optimal way to test and use these drugs has begun. In his Policy Forum, Joep Lange, director of the National AIDS Therapy Evaluation Centre in Amsterdam, takes the controversial stand that suboptimal therapies and drug trial designs are still being used. He discusses the underlying reasons for this situation and the challenges for the future.